KR20170040648A - Pharmaceutical composition for preventing or treating diabetic foot ulcer - Google Patents
Pharmaceutical composition for preventing or treating diabetic foot ulcer Download PDFInfo
- Publication number
- KR20170040648A KR20170040648A KR1020150139908A KR20150139908A KR20170040648A KR 20170040648 A KR20170040648 A KR 20170040648A KR 1020150139908 A KR1020150139908 A KR 1020150139908A KR 20150139908 A KR20150139908 A KR 20150139908A KR 20170040648 A KR20170040648 A KR 20170040648A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- ser
- arg
- pro
- phe
- Prior art date
Links
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 56
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 238000012546 transfer Methods 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 101710151559 Crystal protein Proteins 0.000 claims description 23
- 101710149951 Protein Tat Proteins 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920002704 polyhistidine Polymers 0.000 claims description 9
- 230000026683 transduction Effects 0.000 claims description 9
- 238000010361 transduction Methods 0.000 claims description 9
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 claims description 8
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 description 17
- 108010092114 histidylphenylalanine Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 7
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 7
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 7
- 108010028295 histidylhistidine Proteins 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 108091006106 transcriptional activators Proteins 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 5
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 108010054812 diprotin A Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108010036413 histidylglycine Proteins 0.000 description 5
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 5
- 201000002818 limb ischemia Diseases 0.000 description 5
- 108010026333 seryl-proline Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 4
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 4
- 208000003790 Foot Ulcer Diseases 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 4
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 4
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 4
- WKLMCMXFMQEKCX-SLFFLAALSA-N Phe-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O WKLMCMXFMQEKCX-SLFFLAALSA-N 0.000 description 4
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 4
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 4
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 4
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 4
- VAIWUNAAPZZGRI-IHPCNDPISA-N Ser-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N VAIWUNAAPZZGRI-IHPCNDPISA-N 0.000 description 4
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 108010073101 phenylalanylleucine Proteins 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 3
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 3
- IIAXFBUTKIDDIP-ULQDDVLXSA-N Arg-Leu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IIAXFBUTKIDDIP-ULQDDVLXSA-N 0.000 description 3
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 3
- YNSUUAOAFCVINY-OSUNSFLBSA-N Arg-Thr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YNSUUAOAFCVINY-OSUNSFLBSA-N 0.000 description 3
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 3
- OEUQMKNNOWJREN-AVGNSLFASA-N Asp-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N OEUQMKNNOWJREN-AVGNSLFASA-N 0.000 description 3
- QCLHLXDWRKOHRR-GUBZILKMSA-N Asp-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N QCLHLXDWRKOHRR-GUBZILKMSA-N 0.000 description 3
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 3
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 3
- FTTHLXOMDMLKKW-FHWLQOOXSA-N Gln-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTTHLXOMDMLKKW-FHWLQOOXSA-N 0.000 description 3
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 3
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 3
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 3
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 3
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 3
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 3
- JUBDONGMHASUCN-IUCAKERBSA-N Gly-Glu-His Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O JUBDONGMHASUCN-IUCAKERBSA-N 0.000 description 3
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 3
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- MWAJSVTZZOUOBU-IHRRRGAJSA-N His-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 MWAJSVTZZOUOBU-IHRRRGAJSA-N 0.000 description 3
- JBSLJUPMTYLLFH-MELADBBJSA-N His-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O JBSLJUPMTYLLFH-MELADBBJSA-N 0.000 description 3
- MTHDIEPOBSRDIV-ULQDDVLXSA-N His-Met-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 MTHDIEPOBSRDIV-ULQDDVLXSA-N 0.000 description 3
- AVQNTYBAFBKMDL-WDSOQIARSA-N His-Pro-Trp Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O AVQNTYBAFBKMDL-WDSOQIARSA-N 0.000 description 3
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 3
- 108010065920 Insulin Lispro Proteins 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 3
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 3
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 3
- ZAVCJRJOQKIOJW-KKUMJFAQSA-N Leu-Phe-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=CC=C1 ZAVCJRJOQKIOJW-KKUMJFAQSA-N 0.000 description 3
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 3
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 3
- KKFVKBWCXXLKIK-AVGNSLFASA-N Lys-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)N KKFVKBWCXXLKIK-AVGNSLFASA-N 0.000 description 3
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 3
- ZVZRQKJOQQAFCF-ULQDDVLXSA-N Lys-Tyr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZVZRQKJOQQAFCF-ULQDDVLXSA-N 0.000 description 3
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 3
- WDTLNWHPIPCMMP-AVGNSLFASA-N Met-Arg-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O WDTLNWHPIPCMMP-AVGNSLFASA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 3
- SWCOXQLDICUYOL-ULQDDVLXSA-N Phe-His-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SWCOXQLDICUYOL-ULQDDVLXSA-N 0.000 description 3
- MYQCCQSMKNCNKY-KKUMJFAQSA-N Phe-His-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O)N MYQCCQSMKNCNKY-KKUMJFAQSA-N 0.000 description 3
- CWFGECHCRMGPPT-MXAVVETBSA-N Phe-Ile-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O CWFGECHCRMGPPT-MXAVVETBSA-N 0.000 description 3
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 3
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 3
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 3
- APKRGYLBSCWJJP-FXQIFTODSA-N Pro-Ala-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O APKRGYLBSCWJJP-FXQIFTODSA-N 0.000 description 3
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 3
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 3
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 3
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 3
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 3
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 3
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 3
- QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 3
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 3
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 3
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 3
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 3
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 3
- KDGFPPHLXCEQRN-STECZYCISA-N Tyr-Arg-Ile Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDGFPPHLXCEQRN-STECZYCISA-N 0.000 description 3
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 3
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 3
- PTFPUAXGIKTVNN-ONGXEEELSA-N Val-His-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N PTFPUAXGIKTVNN-ONGXEEELSA-N 0.000 description 3
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 3
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 3
- MLADEWAIYAPAAU-IHRRRGAJSA-N Val-Lys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MLADEWAIYAPAAU-IHRRRGAJSA-N 0.000 description 3
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010079547 glutamylmethionine Proteins 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 2
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 2
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 2
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 2
- YFHATWYGAAXQCF-JYJNAYRXSA-N Arg-Pro-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YFHATWYGAAXQCF-JYJNAYRXSA-N 0.000 description 2
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 2
- GJFYPBDMUGGLFR-NKWVEPMBSA-N Asn-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O GJFYPBDMUGGLFR-NKWVEPMBSA-N 0.000 description 2
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 2
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 2
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 2
- WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 description 2
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IKDOHQHEFPPGJG-FXQIFTODSA-N Gln-Asp-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IKDOHQHEFPPGJG-FXQIFTODSA-N 0.000 description 2
- SRZLHYPAOXBBSB-HJGDQZAQSA-N Glu-Arg-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SRZLHYPAOXBBSB-HJGDQZAQSA-N 0.000 description 2
- XIKYNVKEUINBGL-IUCAKERBSA-N Glu-His-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O XIKYNVKEUINBGL-IUCAKERBSA-N 0.000 description 2
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 2
- AOCARQDSFTWWFT-DCAQKATOSA-N Glu-Met-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AOCARQDSFTWWFT-DCAQKATOSA-N 0.000 description 2
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 2
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RAVLQPXCMRCLKT-KBPBESRZSA-N His-Gly-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RAVLQPXCMRCLKT-KBPBESRZSA-N 0.000 description 2
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 2
- HYWZHNUGAYVEEW-KKUMJFAQSA-N His-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HYWZHNUGAYVEEW-KKUMJFAQSA-N 0.000 description 2
- GIRSNERMXCMDBO-GARJFASQSA-N His-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O GIRSNERMXCMDBO-GARJFASQSA-N 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 2
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 2
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 2
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 2
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 2
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- ZMMDPRTXLAEMOD-BZSNNMDCSA-N Lys-His-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZMMDPRTXLAEMOD-BZSNNMDCSA-N 0.000 description 2
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 2
- XMQSOOJRRVEHRO-ULQDDVLXSA-N Phe-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMQSOOJRRVEHRO-ULQDDVLXSA-N 0.000 description 2
- CKJACGQPCPMWIT-UFYCRDLUSA-N Phe-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CKJACGQPCPMWIT-UFYCRDLUSA-N 0.000 description 2
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 2
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 2
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 2
- GRSLLFZTTLBOQX-CIUDSAMLSA-N Ser-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N GRSLLFZTTLBOQX-CIUDSAMLSA-N 0.000 description 2
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 2
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 2
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 2
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- GQEXFCQNAJHJTI-IHPCNDPISA-N Trp-Phe-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N GQEXFCQNAJHJTI-IHPCNDPISA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- HJWQFFYRVFEWRM-SRVKXCTJSA-N Arg-Arg-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O HJWQFFYRVFEWRM-SRVKXCTJSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- RIIVUOJDDQXHRV-SRVKXCTJSA-N Arg-Lys-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O RIIVUOJDDQXHRV-SRVKXCTJSA-N 0.000 description 1
- QBQVKUNBCAFXSV-ULQDDVLXSA-N Arg-Lys-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QBQVKUNBCAFXSV-ULQDDVLXSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 1
- NTTIDCCSYIDANP-UHFFFAOYSA-N BCCP Chemical compound BCCP NTTIDCCSYIDANP-UHFFFAOYSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 101710180532 Biotin carboxyl carrier protein of acetyl-CoA carboxylase Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101150063057 CRYAB gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- FMBWLLMUPXTXFC-SDDRHHMPSA-N Glu-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N)C(=O)O FMBWLLMUPXTXFC-SDDRHHMPSA-N 0.000 description 1
- RXESHTOTINOODU-JYJNAYRXSA-N Glu-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)O)N RXESHTOTINOODU-JYJNAYRXSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- IBYOLNARKHMLBG-WHOFXGATSA-N Gly-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IBYOLNARKHMLBG-WHOFXGATSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- TXLQHACKRLWYCM-DCAQKATOSA-N His-Glu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O TXLQHACKRLWYCM-DCAQKATOSA-N 0.000 description 1
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 1
- AMSYMDIIIRJRKZ-HJPIBITLSA-N Ile-His-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AMSYMDIIIRJRKZ-HJPIBITLSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- UEEVBGHEGJMDDV-AVGNSLFASA-N Phe-Asp-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UEEVBGHEGJMDDV-AVGNSLFASA-N 0.000 description 1
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 1
- SWZKMTDPQXLQRD-XVSYOHENSA-N Phe-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWZKMTDPQXLQRD-XVSYOHENSA-N 0.000 description 1
- OAOLATANIHTNCZ-IHRRRGAJSA-N Phe-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N OAOLATANIHTNCZ-IHRRRGAJSA-N 0.000 description 1
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 1
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 1
- GNADVDLLGVSXLS-ULQDDVLXSA-N Pro-Phe-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O GNADVDLLGVSXLS-ULQDDVLXSA-N 0.000 description 1
- BUEIYHBJHCDAMI-UFYCRDLUSA-N Pro-Phe-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BUEIYHBJHCDAMI-UFYCRDLUSA-N 0.000 description 1
- HOTVCUAVDQHUDB-UFYCRDLUSA-N Pro-Phe-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 HOTVCUAVDQHUDB-UFYCRDLUSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- VVEQUISRWJDGMX-VKOGCVSHSA-N Pro-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 VVEQUISRWJDGMX-VKOGCVSHSA-N 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108010048304 protamine P4 Proteins 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
본 발명은 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물에 관한 것으로, 더욱 상세하게는 알파B 크리스탈린 단백질과 단백질 전달 도메인의 융합 단백질을 유효성분으로 포함하는, 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic foot ulcers, and more particularly to a pharmaceutical composition for preventing or treating a diabetic foot ulcer comprising an alpha B crystal protein and a fusion protein of a protein transfer domain as an active ingredient ≪ / RTI >
모든 당뇨병 환자의 거의 15%는 일생 중 일정 지점에서 족부궤양이 발병된다(Jeffccoate, W & Harding, K., 2003, Diabetic Foot Ulcers, The Lancet, 362; 154-51), 당뇨병성 족부궤양의 발병에는 여러 경로가 있다. 일반적으로, 당뇨병을 가진 환자의 거의 20%는 불충분한 동맥 혈류(말초 동맥 질환)의 결과로 주로 족부궤양이 발병되며, 50%는 당뇨병성 신경병증에 의해, 30%는 하지 허혈과 당뇨병성 신경병증의 조합에 의해 발병된다. 허혈성 장애 치료에 적합한 모든 방법이 당뇨병성 신경병증에 의해 초래되는 궤양을 치료하는데 사용될 수 있는 것은 아니기 때문에, 이러한 궤양을 예방 및 치료하는데 사용될 수 있는 실행 가능한 방법의 확인이 필요하다(Margolis, D. Hoffstad, O, Allen-Taylor, L., 및 Berlin, J., 2002. Diabetic Nueropathic Foot Ulcers: The association of the wound size, wound duration and wound healing, Diabetes Care 25: 1835-39).Nearly 15% of all diabetics develop foot ulcers at some point in their lifetime (Jeffccoate, W & Harding, K., 2003, Diabetic Foot Ulcers, The Lancet, 362; 154-51), the incidence of diabetic foot ulcers There are several paths to it. In general, nearly 20% of patients with diabetes develop predominantly foot ulcers as a result of insufficient arterial blood flow (peripheral arterial disease), 50% due to diabetic neuropathy, 30% with lower limb ischemia and diabetic neuropathy It is caused by a combination of pathologies. Since not all methods suitable for the treatment of ischemic disorders can be used to treat ulcers caused by diabetic neuropathy, there is a need to identify feasible methods that can be used to prevent and treat such ulcers (Margolis, D. et < RTI ID = 0.0 > Hoffstad, O., Allen-Taylor, L., and Berlin, J., 2002. Diabetic Nueropathic Foot Ulcers: The association of the wound size, wound duration and wound healing, Diabetes Care 25: 1835-39).
또한, 혈관성 다리 궤양(족부 포함)과 당뇨병성 족부궤양을 치료하는데 있어서의 차이점은 보고된 바 있다(Kantor J, Margolis D. Expected Healing Rates for Chronic Wounds, Wounds 12(6): 155-158, 2000). 예를 들어, 혈관성 다리 궤양(VLU)을 가지는 260명의 환자와 당뇨병성 족부궤양(DFU)을 가지는 586명의 환자에 대한 연구에서, 32% VLU가 궤양 치료 24주 후에 치료에 실패한 반면, 67% DFU가 궤양 치료 20주 후 치료에 실패하였다.In addition, differences in the treatment of vascular leg ulcers (including the foot) and diabetic foot ulcers have been reported (Kantor J, Margolis D. Expected Healing Rates for Chronic Wounds, Wounds 12 (6): 155-158, 2000 ). For example, in a study of 260 patients with vascular leg ulcers (VLU) and 586 patients with diabetic foot ulcers (DFU), 32% VLU failed to respond after 24 weeks of ulcer treatment, while 67% DFU Failed to treat after 20 weeks of ulcer treatment.
당뇨병성 신경병증은 당뇨에 의한 신경 손상이 다리와 족부에서 감각을 감소시키는 상태이다. 압박이나 절단에 의해 아물지 않은 부분이 환자에 발병하는 경우에도 환자는 아픔조차 느끼지 못할 것이다. 치료하지 않고 방치하는 경우, 손상된 부분은 빠르게 확대되어 굉장한 조직 파괴를 초래하는 다중미생물에 감염되기 쉬운 당뇨병성 족부궤양으로 발병될 수 있다.Diabetic neuropathy is a condition in which diabetic neuropathy reduces sensation in the legs and feet. Even if the patient does not heal by pressing or cutting, the patient will not feel pain. If left untreated, the damaged area may develop rapidly, leading to diabetic foot ulcers that are susceptible to multiple microorganisms, leading to tremendous tissue destruction.
이러한 감염 과정은 주로 신경병성 궤양을 가지는 환자에서 궤양에 따르는 위험한 절단의 주된 이유이다. 족부궤양에 접근하는 전통적인 치료법에는, 썩은 살의 제거(desloughing) 및 병변절제(debridement), 압박 해소(예, 휴식, 특별한 신발류 및 신발 삽입물 및 캐스팅), 감염의 항생제 치료, 및 상처 드레싱이 포함된다. 특정한 유형의 드레싱은 장애의 치료를 도와주는데 도움을 줄 수 있으나, 이러한 치료법은 종종 비성공적이다.This infection process is the main reason for the dangerous cleavage of the ulcer in patients with mainly neuropathic ulcers. Traditional therapies that approach foot ulcers include desloughing and debridement, relieving stress (eg, rest, special footwear and footwear and casting), antibiotic treatment of infections, and wound dressings. Certain types of dressings can help to treat disability, but these therapies are often unsuccessful.
신경병증성 당뇨병성 족부궤양은 과도한 통증이 있고 쇠약해지며, 천천히 치료될 수 있다. 따라서, 이러한 궤양을 예방 및 치료하는데 사용될 수 있는 실행 가능한 방법을 개발하는 것이 필요한 실정이다.Neuropathic diabetic foot ulcers are over painful, debilitating, and can be treated slowly. It is therefore necessary to develop a viable method that can be used to prevent and treat such ulcers.
본 발명자는 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질이 세포 및 조직 수준에서 혈관 형성을 촉진시킨다는 것을 밝혀냈다. 특히, 본 발명자는 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질이 하지허혈 동물모델에서 생체 내 혈관 형성 촉진함으로써, 당뇨병성 족부궤양의 예방 또는 치료에 유용하게 사용될 수 있다는 것을 발견하였다.The present inventors have found that a fusion protein in which the alpha B crystal protein and the protein transfer domain are fused promotes angiogenesis at the cellular and tissue level. In particular, the present inventors have found that a fusion protein in which an alpha B crystal protein and a protein transfer domain are fused can be useful for the prevention or treatment of diabetic foot ulcer by promoting vascularization in vivo in an ischemic ischemic animal model.
따라서, 본 발명은 상기 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질을 유효성분으로 포함하는 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물을 제공하는 것을 목적으로 한다.Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating a diabetic foot ulcer, which comprises as an active ingredient a fusion protein in which the alpha B crystal protein and the protein transfer domain are fused.
본 발명의 일 태양에 따라, 서열번호 1의 아미노산 서열로 구성된 알파B 크리스탈린(alphaB crystallin) 단백질과 단백질 전달 도메인이 융합된 융합 단백질을 유효성분으로 포함하는, 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물이 제공된다.According to one aspect of the present invention, there is provided a method for preventing or treating a diabetic foot ulcer comprising, as an active ingredient, a fusion protein in which an alpha B crystallin protein consisting of the amino acid sequence of SEQ ID NO: 1 is fused with a protein transfer domain A pharmaceutical composition is provided.
일 구현예에서, 상기 알파B 크리스탈린 단백질을 코딩하는 뉴클레오티드는 서열번호 2의 염기서열로 구성된 것일 수 있다.In one embodiment, the nucleotide encoding the alpha B crystal protein can be comprised of the nucleotide sequence of SEQ ID NO: 2.
다른 구현예에서, 상기 융합 단백질은 상기 알파B 크리스탈린 단백질의 N-말단 또는 C-말단에 서열번호 3의 아미노산 서열로 구성된 TAT 단백질 전달 도메인이 융합된 융합 단백질일 수 있다. 또한 상기 융합 단백질은 알파B 크리스탈린 단백질과 단백질 전달 도메인과의 융합 단백질의 N-말단 또는 C-말단에 폴리 히스티딘 영역이 추가로 융합된 것일 수 있다.In another embodiment, the fusion protein may be a fusion protein in which the TAT protein transfer domain consisting of the amino acid sequence of SEQ ID NO: 3 is fused to the N-terminal or C-terminal of the alpha B crystal protein. The fusion protein may further comprise a fusion of a polyhistidine domain at the N-terminus or C-terminus of the fusion protein of the alpha B crystal protein and the protein transduction domain.
본 발명에 의하여 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질이 세포 및 조직 수준에서 혈관 형성을 촉진시킨다는 것이 밝혀졌다. 특히, 하지허혈 동물모델에서, 상기 융합 단백질이 우수한 생체 내 혈관 형성 촉진 활성을 나타낸다는 것이 본 발명에 의해 밝혀졌다. 따라서, 상기 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질은 당뇨병성 족부궤양의 예방 또는 치료에 유용하게 사용될 수 있다.It has been found by the present invention that a fusion protein in which an alpha B crystal protein and a protein transfer domain are fused promotes angiogenesis at the cellular and tissue level. In particular, in the lower limb ischemia animal model, it has been found by the present invention that the fusion protein exhibits excellent in vivo angiogenesis promoting activity. Therefore, the fusion protein in which the alpha B crystal protein and the protein transfer domain are fused can be useful for the prevention or treatment of diabetic foot ulcers.
도 1은 pHis/TAT-알파B 크리스탈린 발현 벡터의 개열지도를 나타낸다.
도 2는 사람의 알파B 크리스탈린 유전자를 pHis/TAT 발현 벡터에 도입하여 대장균에 형질전환한 후 단백질 발현 및 정제를 통해 얻어진 융합 단백질(TAT-알파B 크리스탈린 단백질, 서열번호 10)을 쿠마쉬 브릴리언트 블루(Coomassie brilliant blue)로 염색한 결과를 나타낸다.
도 3은 혈관내피세포(HUVECs)에 본 발명의 융합 단백질을 처리하여 혈관 형성 여부를 측정한 결과이다.
도 4는 랫트 대동맥을 적출하여 본 발명의 융합 단백질을 처리한 후, 혈관 형성 여부를 측정하여 얻어진 랫트 대동맥 성장 분석(rat aortic sprouting assay) 결과이다.
도 5는 마우스 하지허혈 모델에서 혈관 형성 및 혈류 개선 효과를 측정하여 얻어진 결과이다.
도 6은 도 5의 결과를 수치화하여 나타낸 그래프이다.Figure 1 shows the cleavage map of the pHis / TAT-alpha B crystallin expression vector.
FIG. 2 shows a result obtained by introducing a human alpha-B crystal gene into a pHis / TAT expression vector and transforming it into Escherichia coli. The fusion protein (TAT-alpha B cristalline protein, SEQ ID NO: 10) The result is stained with Coomassie brilliant blue.
FIG. 3 shows the result of measuring the angiogenesis by treating the endothelial cells (HUVECs) with the fusion protein of the present invention.
FIG. 4 is a rat aortic sprouting assay result obtained by measuring the formation of blood vessels after treating the fusion protein of the present invention by extracting the rat aorta.
FIG. 5 shows the results obtained by measuring the angiogenesis and blood flow improvement effect in a mouse ischemic model.
6 is a graph showing the results of FIG. 5 in numerical form.
본 발명은 서열번호 1의 아미노산 서열로 구성된 알파B 크리스탈린(alphaB crystallin) 단백질과 단백질 전달 도메인이 융합된 융합 단백질을 유효성분으로 포함하는, 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating a diabetic foot ulcer comprising, as an active ingredient, a fusion protein in which an alpha B crystallin protein consisting of the amino acid sequence of SEQ ID NO: 1 is fused with a protein transfer domain .
알파B 크리스탈린(alphaB crystallin)은 CRYAB 유전자에 의해 코딩된 단백질이다. 알파B 크리스탈린은 열충격 단백질 군의 일부이며, 주로 잘못 중첩된(misfolded) 단백질에 결합하여 단백질 응집을 방지하고 세포사멸을 방지하는 분자 차페론(molecular chaperone)으로서 기능한다. 이 유전자/단백질의 결여는 암 및 알츠하이머 질환, 파킨슨 질환과 같은 퇴해성 뇌질환과 연관된다. 본 발명에 의해, 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질이 세포 및 조직 수준에서 혈관 형성을 촉진시킨다는 것이 밝혀졌다. 특히, 하지허혈 동물모델에서, 상기 융합 단백질이 우수한 생체 내 혈관 형성 촉진 활성을 나타낸다는 것이 본 발명에 의해 밝혀졌다. 따라서, 상기 알파B 크리스탈린 단백질과 단백질 전달 도메인이 융합된 융합 단백질은 당뇨병성 족부궤양의 예방 또는 치료에 유용하게 사용될 수 있다.Alpha B crystallin is a protein encoded by the CRYAB gene. Alpha B cristalline is part of the heat shock protein family and functions primarily as a molecular chaperone that binds to misfolded proteins to prevent protein aggregation and prevent cell death. Lack of this gene / protein is associated with retinal brain diseases such as cancer and Alzheimer's disease, Parkinson's disease. It has been found by the present invention that a fusion protein in which an alpha B crystal protein and a protein transfer domain are fused promotes angiogenesis at the cellular and tissue level. In particular, in the lower limb ischemia animal model, it has been found by the present invention that the fusion protein exhibits excellent in vivo angiogenesis promoting activity. Therefore, the fusion protein in which the alpha B crystal protein and the protein transfer domain are fused can be useful for the prevention or treatment of diabetic foot ulcers.
본 발명의 약학 조성물에 있어서, 상기 알파B 크리스탈린 단백질은 서열번호 1의 아미노산 서열로 구성되며, 이를 코딩하는 뉴클레오티드는 바람직하게는 서열번호 2의 염기서열로 구성된 뉴클레오티드일 수 있다. In the pharmaceutical composition of the present invention, the alpha B cristalline protein is composed of the amino acid sequence of SEQ ID NO: 1, and the nucleotide encoding it is preferably a nucleotide consisting of the nucleotide sequence of SEQ ID NO: 2.
상기 단백질 전달 도메인은 세포 내로 단백질을 전달할 수 있는 단백질로서, 예를 들어, 인간 면역결핍 바이러스 타입 I(HIV-1)에서 유래한 TAT(trans-activating transcriptional activator); 초파리의 안테나페디아 호메오도메인(Antennapedia Homeodomain)인 Antp(Antennapedia 또는 penetratin) 펩타이드; 쥐의 전사인자의 Mph-1(Mutator phenotype protein 1), HSV-1(Herpes simplex virus)의 VP22(viral protein 22); 청어 프로타민의 HP4(human protamine P4); 또는 이들의 변형 펩타이드(예를 들면, TAT 단백질의 47-57 아미노산 잔기 또는 이를 변형한 펩타이드)로 이루어진 군에서 선택될 수 있다. 상기 융합 단백질은 생물공학 분야에서 통상적으로 사용되는 방법에 의해 제조될 수 있다. 예를 들어, 알파B 크리스탈린 유전자(바람직하게는, 서열번호 2의 유전자)를 PCR 방법으로 DNA 단편을 얻어 단백질 전달 도메인이 포함된 플라스미드 벡터(원핵세포 발현용 벡터 pET 등 또는 진핵 세포 발현용 벡터 pcDNA 등)에 도입한 후 발현용 세포에 형질전환시켜 단백질 발현시킴으로써 제조될 수 있다.The protein transfer domain is a protein capable of transferring a protein into a cell, for example, a trans-activating transcriptional activator (TAT) derived from human immunodeficiency virus type I (HIV-1); Antp (Antennapedia or penetratin) peptide which is an Antennapedia Homeodomain; Mutant phenotype protein 1 (Mph-1) of the mouse transcription factor, VP22 of HSV-1 (Herpes simplex virus); HP4 (human protamine P4) of herring protamine; Or a modified peptide thereof (for example, a 47-57 amino acid residue of the TAT protein or a peptide modified therefrom). The fusion protein can be produced by a method commonly used in the field of biotechnology. For example, a DNA fragment can be obtained by PCR using the alpha B crystal gene (preferably, the gene of SEQ ID NO: 2) and a plasmid vector containing the protein transduction domain (vector for prokaryotic expression pET or the vector for eukaryotic expression pcDNA and the like), transforming the cells for expression, and expressing the protein.
일 구현예에서, 상기 융합 단백질은 상기 알파B 크리스탈린 단백질의 N-말단 또는 C-말단에 서열번호 3의 아미노산 서열로 구성된 TAT 단백질 전달 도메인이 융합된 융합 단백질일 수 있으며, 예를 들어, 상기 알파B 크리스탈린 단백질의 N-말단에 서열번호 3의 아미노산 서열로 구성된 TAT 단백질 전달 도메인이 융합된 융합 단백질, 즉, 서열번호 4의 아미노산 서열로 구성된 융합 단백질일 수 있다. 상기 융합 단백질은 상기 TAT 단백질 전달 도메인과 상기 알파B 크리스탈린 단백질 사이에 1 내지 5개의 아미노산으로 구성된 링커 단백질을 포함할 수 있다. 상기 링커 단백질은 알파B 크리스탈린 유전자를 TAT 단백질 전달 도메인이 포함된 플라스미드 벡터에 클로닝하는 과정에서 도입되는 서열일 수 있으며, 예를 들어 -Gly-Ser-Gly-Phe-의 서열로 구성될 수 있다. 따라서, 상기 융합 단백질은 상기 TAT 단백질 전달 도메인과 상기 알파B 크리스탈린 단백질 사이에 -Gly-Ser-Gly-Phe-의 서열로 구성된 링커 단백질을 포함하는 단백질(예를 들어, 서열번호 5의 아미노산 서열로 구성된 융합 단백질)일 수 있다. 또한, 상기 알파B 크리스탈린 단백질과 TAT 단백질 전달 도메인과의 융합 과정에서, 알파B 크리스탈린 단백질의 N-말단의 첫번째 아미노산인 메티오닌(Met)가 결실될 수 있다. 따라서, 상기 융합 단백질은 상기 TAT 단백질 전달 도메인과 상기 알파B 크리스탈린 단백질 사이에 -Gly-Ser-Gly-Phe-의 서열로 구성된 링커 단백질을 포함하고, 상기 알파B 크리스탈린 단백질의 N-말단의 첫번째 아미노산이 결실된 단백질(예를 들어, 서열번호 6의 아미노산 서열로 구성된 융합 단백질)일 수 있다. In one embodiment, the fusion protein may be a fusion protein in which the TAT protein transduction domain consisting of the amino acid sequence of SEQ ID NO: 3 is fused to the N-terminal or C-terminal of the alpha B crystal protein, A fusion protein consisting of the amino acid sequence of SEQ ID NO: 4, or a fusion protein in which the TAT protein transduction domain consisting of the amino acid sequence of SEQ ID NO: 3 is fused at the N-terminus of the alpha B crystal protein. The fusion protein may comprise a linker protein consisting of between one and five amino acids between the TAT protein transfer domain and the alpha B crystallin protein. The linker protein may be a sequence introduced during the cloning of the alpha B crystal gene into a plasmid vector containing the TAT protein transfer domain, for example, a sequence of -Gly-Ser-Gly-Phe- . Thus, the fusion protein comprises a protein comprising a linker protein consisting of a sequence of -Gly-Ser-Gly-Phe- between the TAT protein transfer domain and the alpha B crystalin protein (e. G., The amino acid sequence of SEQ ID NO: 5 ≪ / RTI > Also, in the process of fusion of the alpha B crystal protein with the TAT protein transduction domain, methionine (Met), the first amino acid of the N-terminal of alpha B crystallin protein, may be deleted. Thus, the fusion protein comprises a linker protein consisting of a sequence of -Gly-Ser-Gly-Phe- between the TAT protein transfer domain and the alpha B crystal protein, and the N-terminal The first amino acid may be a deleted protein (e. G., A fusion protein consisting of the amino acid sequence of SEQ ID NO: 6).
또한, 상기 융합 단백질은 폴리 히스티딘 영역을 추가로 포함할 수 있다. 일 구현예에서, 폴리 히스티딘 영역을 포함하는 융합 단백질은 알파B 크리스탈린 단백질과 단백질 전달 도메인과의 융합 단백질의 N-말단 또는 C-말단에 폴리 히스티딘 영역이 추가로 융합된 단백질일 수 있다. 상기 폴리 히스티딘 영역은 본 기술분야에서 통상적으로 사용되는 His-tag 서열일 수 있으며, 예를 들어 단백질 정제(예를 들어, 친화성 크로마토그래피(affinity chromatography))를 위한 His-tag 서열 또는 다른 펩타이드 또는 단백질 서열일 수 있으며, 예를 들어 S-tag, T7-tag, HA-tag, FLAG-tag, myc-tag, E-tag, V5-tag, Fc-tag, VSV-tag, Xpress-tag, 스트렙트아비딘 결합 단백질(streptavidin binding protein, SBP)-tag, 글루타치온 S-트랜스퍼라아제(glutathione S-transferase, GST)-tag, 말토오즈-결합 단백질(maltose-binding protein, MBP)-tag, 티오레독신(thioredoxin)-tag, 키틴 결합 도메인(chitin binding domain, CBD)-tag, 케토스테로이드 아이소머라아제(ketosteroid isomerase, KSI)-tag, 디히드로폴레이트 리덕타아제(dihydrofolate reductase, DHFR)-tag), NusA-tag, intein-tag, polu(NANP)-tag, 바이오틴 카르복실 담체 단백질(biotin carboxyl carrier protein, BCCP)-tag, 형광 단백질(예를 들어, 그린 형광 단백질(green fluorescent protein, GFP)-tag) 등을 포함한 공지의 tag 서열일 수 있다. 일 구현예에서, 상기 폴리 히스티딘 영역은 서열번호 7의 아미노산 서열로 구성될 수 있으며, 얻어진 융합 단백질은 서열번호 8 내지 10의 아미노산 서열로 구성된 융합 단백질일 수 있다. In addition, the fusion protein may further comprise a polyhistidine region. In one embodiment, the fusion protein comprising the polyhistidine region may be a protein in which the polyhistidine region is further fused to the N-terminus or C-terminus of the fusion protein of the alpha B crystal protein and the protein transfer domain. The polyhistidine region may be a His-tag sequence commonly used in the art and may be, for example, a His-tag sequence for protein purification (e. G., Affinity chromatography) Tag, a T-tag, a HA-tag, a FLAG-tag, a myc-tag, an E-tag, a V5-tag, an Fc-tag, a VSV-tag, Streptavidin binding protein (SBP) -tag, glutathione S-transferase (GST) -tag, maltose-binding protein (MBP) -tag, thioredoxin a thioredoxin-tag, a chitin binding domain (CBD) -tag, a ketosteroid isomerase (KSI) -tag, a dihydrofolate reductase (DHFR) -tag, NuA-tag, intein-tag, polu (NANP) -tag, biotin carboxyl carrier protein, BCCP) -tag, a fluorescent protein (for example, green fluorescent protein (GFP) -tag), and the like. In one embodiment, the polyhistidine region may comprise the amino acid sequence of SEQ ID NO: 7, and the resulting fusion protein may be a fusion protein comprising the amino acid sequence of SEQ ID NOs: 8-10.
본 발명의 약학 조성물은 약학적으로 허용가능한 담체를 포함할 수 있으며, 통상의 방법에 따라 액제, 현탁액, 에멀젼, 로오숀제, 연고제, 동결건조제 등의 국소투여를 위한 비경구용 제형으로 제제화될 수 있다. 상기 약학적으로 허용가능한 담체는 인산 완충 식염수(phosphate buffered saline), 정제수, 멸균수 등의 수성 희석제 혹은 용제를 포함하며, 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일등의 비수성 희석제 혹은 용제를 포함한다. 또한, 필요에 따라 습윤제, 방향제, 보존제 등을 포함할 수 있다. 상기 약학 조성물에 함유되는 상기 융합 단백질의 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 예를 들면, 상기 융합 단백질은 예를 들어, 1일 0.01 내지 10 mg/kg, 바람직하게는 0.1 내지 1 mg/kg의 양으로 투여할 수 있으며, 상기 투여는 하루에 한번 또는 수회 나누어 투여할 수도 있다.The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier and may be formulated into a parenteral formulation for topical administration such as a liquid, a suspension, an emulsion, an ointment, an ointment, or a lyophilizate according to a conventional method . The pharmaceutically acceptable carrier includes an aqueous diluent or solvent such as phosphate buffered saline, purified water, sterilized water, etc., and may be a non-aqueous diluent such as propylene glycol, polyethylene glycol, olive oil, . Further, if necessary, it may contain a wetting agent, a fragrance, a preservative, and the like. The dose of the fusion protein contained in the pharmaceutical composition varies depending on the condition and body weight of the patient, the severity of the disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. For example, the fusion protein may be administered in an amount of, for example, 0.01 to 10 mg / kg, preferably 0.1 to 1 mg / kg per day, which may be administered once a day or several times have.
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrating the present invention, and the scope of the present invention is not limited to these examples.
실시예Example 1: 융합 단백질의 제조 1: Preparation of fusion protein
알파B 크리스탈린 단백질과 TAT 단백질 전달 도메인의 융합 단백질은 pHis/TAT 발현 벡터(Kwon JH et al., 2007, Biochem Biophys Res Commun., 363, 399-404)를 이용하여 재조합 단백질 발현 및 정제에 의해 제조하였다. 서열번호 2의 알파B 크리스탈린 cDNA를 주형으로 하여 다음의 두 가지 프라이머 5'-CTATCAGAATTCGACATCGCCATCCACCAC-3' (서열번호 11, 밑줄 EcoRI 제한효소부위), 5'-TACCGACTCGAGCTATTTCTTGGGGGCTGC-3' (서열번호 12, 밑줄 XhoI 제한효소부위)를 이용하여 중합효소연쇄반응을 통하여 DNA 단편(서열번호 13)을 얻어 각각의 제한효소(EcoRI/XhoI)로 잘라 pHis/TAT 발현 벡터에 넣어 재조합 발현벡터 pHis/TAT-알파B-크리스탈린을 제작하였고(도 1), 이를 대장균 BL21(DE3)에 형질도입시켰다. 단백질 발현을 위해 600 nm에서의 흡광도가 0.5에 이를 때까지 배양한 후 IPTG(isopropyl-β-D-thio-galactoside)를 첨가하여 4시간 추가 배양하였다. 배양된 대장균을 원심분리로 회수하여 초음파 분쇄기로 파쇄한 후, Ni-NTA 친화성 컬럼 크로마토그래피(Ni-NTA affinity column chromatography) 방법으로 TAT-알파B 크리스탈린 단백질(서열번호 10)을 분리하였다. 정제된 단백질은 쿠마쉬 브릴리언트 블루(Coomassie brilliant blue)로 염색하여 확인하였다(도 2).The fusion protein of the alpha B crystal protein and the TAT protein transduction domain was purified by recombinant protein expression and purification using the pHis / TAT expression vector (Kwon JH et al., 2007, Biochem Biophys Res Commun., 363, 399-404) . SEQ ID NO: 2 in the alpha crystalline B cDNA as the template and the following two primers of 5'-CTATCA GAATTC GACATCGCCATCCACCAC-3 ' ( SEQ ID NO: 11, underlined EcoRI restriction site), 5'-TACCGA CTCGAG CTATTTCTTGGGGGCTGC- 3' ( SEQ ID NO: DNA fragment (SEQ ID NO: 13) was obtained by polymerase chain reaction using a restriction enzyme (EcoRI / XhoI), and inserted into a pHis / TAT expression vector to obtain a recombinant expression vector pHis / TAT-alpha B-cristalline was prepared (Fig. 1), which was transformed into E. coli BL21 (DE3). For protein expression, IPTG (isopropyl-β-D-thio-galactoside) was added to the solution until the absorbance at 600 nm reached 0.5 and further incubated for 4 hours. The cultured Escherichia coli was recovered by centrifugation, disrupted by an ultrasonic grinder, and then subjected to Ni-NTA affinity column chromatography to separate TAT-alpha B crystalin protein (SEQ ID NO: 10). The purified protein was identified by staining with Coomassie brilliant blue (Fig. 2).
실시예Example 2: 혈관내피세포의 혈관 형성 촉진 효과 2: Promoting angiogenesis of vascular endothelial cells
세포 수준에서 혈관 형성 여부를 확인하기 위하여, 혈관내피세포(Human Umbilical Vein Endothelial Cells, HUVECs)와 마트리겔이 코팅된 96-웰 플레이트(ECMatrix, Millipore)를 사용하였다. 혈관 형성 분석 1시간 전에, 마트리겔을 96-웰 플레이트의 각 웰에 50 ㎕씩 넣고, 37℃에서 인큐베이션하여 마트리겔 플레이트(matrigel plate)를 만들었다. 6-웰 플레이트에서 HUVECs을 EBM 배지(Lonza)와 함께 배양한 후, 실시예 1에서 얻어진 서열번호 10의 TAT-알파B 크리스탈린 단백질을 1 nM, 10 nM, 100 nM, 및 1 μM의 농도로 처리하여 24시간 동안 추가배양하였다. 이때, EBM 배지 대조군(음성 대조군, 세포성장인자가 포함되어 있지 않은 배지) 및 EGM 배지 대조군(양성 대조군, 세포성장인자들(2% 우태아혈청(fetal bovine serum), 0.4% 히드로코르티손(hydrocortisone), 4% hFGF-B, 0.1% VEGF, 0.1% R3-IGF, 0.1% 아스코르브산, 0.1% hEGF, 0.1% GA-1000, 0.1% 헤파린)이 포함된 배지)도 함께 시험하였다. 배양 완료 후, 세포를 수확하여, 상기에서 준비한 마트리겔 플레이트에 2 X 104 세포를 각각 시딩하고, 16시간 이후 역상현미경과 연결된 CCD 카메라로 촬영하였다(도 3). 도 3의 결과로부터, EBM 배지 대조군에 비하여 TAT-알파B 크리스탈린 단백질 처리군에서 혈관 형성이 현저하게 촉진됨을 알 수 있다.To determine the angiogenesis at the cellular level, 96-well plates (ECMatrix, Millipore) coated with Human Umbilical Vein Endothelial Cells (HUVECs) and Matrigel were used. One hour before angiogenesis analysis, Matrigel was added to each well of a 96-well plate in an amount of 50 占 퐇 and incubated at 37 占 폚 to make a matrigel plate. After culturing HUVECs in a 6-well plate with EBM medium (Lonza), the TAT-alpha B crystallin protein of SEQ ID NO: 10 obtained in Example 1 was incubated at a concentration of 1 nM, 10 nM, 100 nM, Lt; / RTI > for 24 hours. At this time, the EBM medium control group (negative control, medium containing no cell growth factor) and EGM medium control group (positive control, cell growth factors (2% fetal bovine serum, 0.4% hydrocortisone, , 4% hFGF-B, 0.1% VEGF, 0.1% R3-IGF, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000 and 0.1% heparin). After completion of the cultivation, the cells were harvested, 2 x 10 4 cells were seeded on the matrigel plate prepared above, and the cells were photographed with a CCD camera connected with a reversed-phase microscope after 16 hours (Fig. 3). From the results of FIG. 3, it can be seen that angiogenesis is significantly promoted in the TAT-alpha B crystal protein-treated group compared to the EBM medium control group.
실시예Example 3: 3: 랫트Rat 대동맥을 이용한 혈관 형성 촉진 효과 Promotion of angiogenesis using aorta
조직 수준에서 혈관 형성 여부를 확인하기 위하여, 랫트 대동맥 성장 분석(rat aortic sprouting assay)을 수행하였다. 약 200 g의 SD 랫트에 졸레틸(30 mg/kg)과 럼푼(10 mg/kg)을 섞어 복강으로 주입하였다. 심마취가 유도된 것을 확인 후, 흉곽부위를 개복하여 복대동맥을 3 cm 정도 적출해 생리식염수에 담궈 복대동맥 내에 들어있는 혈액을 제거하여, 두께 1 mm 이하가 되도록 메스를 이용하여 잘랐다. 이를 링(ring)모양이 유지되도록 하여, 실시예 2와 동일한 방법으로 준비한 마트리겔 플레이트에 옮긴 후, 100 μL의 EGM 배지(Lonza)를 넣고 약 2일 동안 안정시킨 후, EBM 배지(Lonza)로 바꾸고 여기에 실시예 1에서 얻어진 서열번호 10의 TAT-알파B 크리스탈린 단백질을 1 nM, 10 nM, 100 nM, 및 1 μM의 농도로 처리하였다. 이때, EBM 배지 대조군(음성 대조군, 세포성장인자가 포함되어 있지 않은 배지만을 처리) 및 EGM 배지 대조군(양성 대조군, 세포성장인자들(2% 우태아혈청, 0.4% 히드로코르티손, 4% hFGF-B, 0.1% VEGF, 0.1% R3-IGF, 0.1% 아스코르브산, 0.1% hEGF, 0.1% GA-1000, 0.1% 헤파린)이 포함된 배지만을 처리)도 함께 시험하였다. 3일 후 역상현미경과 연결된 CCD 카메라로 촬영하였다(도 4). 도 4의 결과로부터, EBM 배지 대조군에 비하여 TAT-알파B 크리스탈린 단백질 처리군에서 랫트 대동맥으로부터의 혈관형성이 현저하게 촉진됨을 알 수 있다.A rat aortic sprouting assay was performed to confirm the formation of blood vessels at the tissue level. Approximately 200 g SD rats were injected intraperitoneally with a mixture of zoletile (30 mg / kg) and rumun (10 mg / kg). After confirming the induction of deep anesthesia, the thoracic region was opened, the abdominal aorta was removed about 3 cm, and the blood in the abdominal aorta was removed by immersion in physiological saline, and the blood was cut using a scalpel to a thickness of 1 mm or less. Then, 100 μL of EGM medium (Lonza) was added to the plate and allowed to stand for about 2 days. Then, the plate was incubated with EBM medium (Lonza) And the TAT-alpha B crystalin protein of SEQ ID NO: 10 obtained in Example 1 was treated at a concentration of 1 nM, 10 nM, 100 nM, and 1 μM. The cells were treated with EBM medium control (negative control, treatment of embryos free of cell growth factor) and EGM medium control (positive control, cell growth factors (2% fetal bovine serum, 0.4% hydrocortisone, 4% hFGF-B , 0.1% VEGF, 0.1% R3-IGF, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000, 0.1% heparin). Three days later, a CCD camera connected to a reversed-phase microscope was used (FIG. 4). From the results of FIG. 4, it can be seen that angiogenesis from the rat aorta is markedly promoted in the TAT-alpha B crystal protein-treated group compared to the EBM medium control group.
실시예Example 4: 마우스 4: Mouse 하지허혈Ischemia 모델에서 혈관 형성 및 혈류개선 효과 Improvement of angiogenesis and blood flow in model
하지허혈 동물모델(hind limb ischemia model)에서 혈관 형성 및 혈류 개선 효과를 확인하였다. 6주령의 C57/BL6 마우스에 졸레틸(30 mg/kg)과 럼푼(10 mg/kg)을 섞어 복강으로 주입하여 마취시켰다. 각 시험군의 허혈 모델 이전 혈류 흐름을 레이저 도플러 이미지 시스템(Laser Doppler Image System)(MoorLDI2TM, Moor Instruments, Axminster, UK)을 사용하여 측정하였다. 하지허혈 모델 제작을 위해 좌측하지 허벅지부위의 피부와 피하조직을 절개한 후, 사타구니 하방부터 슬와동맥 상방까지의 대퇴부동맥과 그로부터 분지되는 동맥들을 묶었다. 묶여진 대퇴부 동맥을 절개하여 들어내고, 절개 부위를 봉합하여 하지허혈 모델을 제작하였다. 이후 대퇴부 근육에 임의의 네곳의 부위에 약물을 주입하였다. 약물의 주입은 생리식염수(200 μl), TAT-EGFP(enhanced green fluorescent protein)(1 ㎍/ml), VEGF(vascular endothelial growth factor)(1 ㎍/ml), 및 실시예 1에서 얻어진 서열번호 10의 TAT-알파B 크리스탈린 단백질(1 ㎍/ml)을 200 ㎕의 용량으로 만들어 50 ㎕씩 네곳에 나누어 주입하였다. 이후 4, 7, 11일째에 레이저 도플러 이미지 시스템을 이용하여 혈류 흐름을 측정하였다(도 5). 도 5에서 saline, GFP, VEGF, TAT-ABCY는 각각 대조 생리식염수 처리군, 대조 TAT-EGFP 처리군, 대조 VEGF 처리군, 및 TAT-알파B 크리스탈린 단백질 처리군을 나타낸다. 상기 TAT-EGFP 처리군은 TAT-알파B 크리스탈린 단백질의 효과가 세포내 전달체로서 사용한 TAT 펩타이드의 영향이 아닌 알파B 크리스탈린 단백질이 세포/조직내로 들어가서 효과를 나타내는지 여부를 확인하기 위한 시험군이다. 상기 VEGF 처리군은 성장인자들 가운데 혈관 형성 촉진 효과를 갖는 단백질로 알려진 성장인자이며, 양성 대조군으로 사용하였다. 도 6은 도 5로부터 얻어진 각각의 결과를 수치화하여 그래프로 나타낸 것이다. 도 5 및 도 6의 결과로부터, TAT-알파B 크리스탈린 단백질 처리군은 우수한 생체 내 혈관 형성 촉진 활성을 나타냄을 확인할 수 있다.(Hind limb ischemia model). The effect of angiogenesis and blood flow improvement was confirmed in the hind limb ischemia model. Six-week old C57 / BL6 mice were anesthetized by intraperitoneal injection of Zoletil (30 mg / kg) and rumun (10 mg / kg). The blood flow prior to the ischemic model of each test group was measured using a Laser Doppler Image System (MoorLDI2TM, Moor Instruments, Axminster, UK). In order to construct the lower limb ischemic model, the skin and subcutaneous tissues of the left lower thigh region were incised, and the femoral artery from below the groin to the upper portion of the dorsal artery and the arteries branching therefrom were bound together. The bundled femoral artery was incised and lifted, and the incision site was sutured to create the lower limb ischemic model. Thereafter, the drug was injected into any four sites on the thigh muscles. Injection of the drug was carried out using physiological saline (200 μl), enhanced green fluorescent protein (TEG-EGFP) (1 μg / ml), vascular endothelial growth factor (VEGF) Of TAT-alpha B crystallin protein (1 / / ml) was injected in 50 μl aliquots into 200 μl aliquots. On the 4th, 7th, and 11th days, the flow of blood was measured using a laser Doppler imaging system (FIG. 5). In FIG. 5, saline, GFP, VEGF, and TAT-ABCY are treated with a control physiological saline solution, a control TAT-EGFP treatment group, a control VEGF treatment group, and a TAT-alpha B crystaline protein treatment group. The TAT-EGFP-treated group is a test group to confirm whether the effect of TAT-alpha B cristalline protein is not influenced by the TAT peptide used as an intracellular transporter but the alpha B crystal protein enters the cell / to be. The VEGF-treated group is a growth factor known as a protein having an effect of promoting angiogenesis among growth factors and used as a positive control. 6 is a graphical representation of each result obtained from FIG. From the results shown in FIG. 5 and FIG. 6, it can be confirmed that the TAT-alpha B crystalin protein-treated group exhibits excellent in vivo angiogenesis promoting activity.
<110> College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation <120> Pharmaceutical composition for preventing or treating diabetic foot ulcer <130> PN0755 <160> 13 <170> KopatentIn 2.0 <210> 1 <211> 175 <212> PRT <213> homo sapiens <400> 1 Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro 1 5 10 15 Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu 20 25 30 Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr 35 40 45 Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly 50 55 60 Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp 65 70 75 80 Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp 85 90 95 Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly 100 105 110 Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val 115 120 125 Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr 130 135 140 Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro 145 150 155 160 Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 165 170 175 <210> 2 <211> 525 <212> DNA <213> homo sapiens <400> 2 atggacatcg ccatccacca cccctggatc cgccgcccct tctttccttt ccactccccc 60 agccgcctct ttgaccagtt cttcggagag cacctgttgg agtctgatct tttcccgacg 120 tctacttccc tgagtccctt ctaccttcgg ccaccctcct tcctgcgggc acccagctgg 180 tttgacactg gactctcaga gatgcgcctg gaaaaggaca ggttctctgt caacctggat 240 gtgaagcact tctccccaga ggaactcaaa gttaaggtgt tgggagatgt gattgaggtg 300 catggaaaac atgaagagcg ccaggatgaa catggtttca tctccaggga gttccacagg 360 aaataccgga tcccagctga tgtagaccct ctcaccatta cttcatccct gtcatctgat 420 ggggtcctca ctgtgaatgg accaaggaaa caggtctctg gccctgagcg caccattccc 480 atcacccgtg aagagaagcc tgctgtcacc gcagccccca agaaa 525 <210> 3 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> TAT protein transduction domain <400> 3 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 10 <210> 4 <211> 186 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 4 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Asp Ile Ala Ile 1 5 10 15 His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe His Ser Pro Ser 20 25 30 Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu Glu Ser Asp Leu 35 40 45 Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu Arg Pro Pro Ser 50 55 60 Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu Ser Glu Met Arg 65 70 75 80 Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val Lys His Phe Ser 85 90 95 Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val Ile Glu Val His 100 105 110 Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe Ile Ser Arg Glu 115 120 125 Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp Pro Leu Thr Ile 130 135 140 Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val Asn Gly Pro Arg 145 150 155 160 Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile Thr Arg Glu Glu 165 170 175 Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 <210> 5 <211> 190 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 5 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ser Gly Phe Met 1 5 10 15 Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe 20 25 30 His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu 35 40 45 Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu 50 55 60 Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu 65 70 75 80 Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val 85 90 95 Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val 100 105 110 Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe 115 120 125 Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp 130 135 140 Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val 145 150 155 160 Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile 165 170 175 Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 190 <210> 6 <211> 189 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 6 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ser Gly Phe Asp 1 5 10 15 Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe His 20 25 30 Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu Glu 35 40 45 Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu Arg 50 55 60 Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu Ser 65 70 75 80 Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val Lys 85 90 95 His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val Ile 100 105 110 Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe Ile 115 120 125 Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp Pro 130 135 140 Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val Asn 145 150 155 160 Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile Thr 165 170 175 Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 <210> 7 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Polyhistidine tag <400> 7 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met 20 <210> 8 <211> 207 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 8 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro 35 40 45 Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu 50 55 60 Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr 65 70 75 80 Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly 85 90 95 Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp 100 105 110 Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp 115 120 125 Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly 130 135 140 Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val 145 150 155 160 Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr 165 170 175 Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro 180 185 190 Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 195 200 205 <210> 9 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 9 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Gly Ser Gly Phe Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg 35 40 45 Pro Phe Phe Pro Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe 50 55 60 Gly Glu His Leu Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu 65 70 75 80 Ser Pro Phe Tyr Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp 85 90 95 Phe Asp Thr Gly Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser 100 105 110 Val Asn Leu Asp Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys 115 120 125 Val Leu Gly Asp Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln 130 135 140 Asp Glu His Gly Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile 145 150 155 160 Pro Ala Asp Val Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp 165 170 175 Gly Val Leu Thr Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu 180 185 190 Arg Thr Ile Pro Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala 195 200 205 Pro Lys Lys 210 <210> 10 <211> 210 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 10 Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Gly Ser Gly Phe Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro 35 40 45 Phe Phe Pro Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly 50 55 60 Glu His Leu Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser 65 70 75 80 Pro Phe Tyr Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe 85 90 95 Asp Thr Gly Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val 100 105 110 Asn Leu Asp Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val 115 120 125 Leu Gly Asp Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp 130 135 140 Glu His Gly Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro 145 150 155 160 Ala Asp Val Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly 165 170 175 Val Leu Thr Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg 180 185 190 Thr Ile Pro Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro 195 200 205 Lys Lys 210 <210> 11 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 11 ctatcagaat tcgacatcgc catccaccac 30 <210> 12 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 12 taccgactcg agctatttct tgggggctgc 30 <210> 13 <211> 549 <212> DNA <213> Artificial Sequence <220> <223> DNA fragment <400> 13 ctatcagaat tcgacatcgc catccaccac ccctggatcc gccgcccctt ctttcctttc 60 cactccccca gccgcctctt tgaccagttc ttcggagagc acctgttgga gtctgatctt 120 ttcccgacgt ctacttccct gagtcccttc taccttcggc caccctcctt cctgcgggca 180 cccagctggt ttgacactgg actctcagag atgcgcctgg aaaaggacag gttctctgtc 240 aacctggatg tgaagcactt ctccccagag gaactcaaag ttaaggtgtt gggagatgtg 300 attgaggtgc atggaaaaca tgaagagcgc caggatgaac atggtttcat ctccagggag 360 ttccacagga aataccggat cccagctgat gtagaccctc tcaccattac ttcatccctg 420 tcatctgatg gggtcctcac tgtgaatgga ccaaggaaac aggtctctgg ccctgagcgc 480 accattccca tcacccgtga agagaagcct gctgtcaccg cagcccccaa gaaatagctc 540 gagtcggta 549 <110> College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation <120> Pharmaceutical composition for preventing or treating diabetic foot ulcer <130> PN0755 <160> 13 <170> Kopatentin 2.0 <210> 1 <211> 175 <212> PRT <213> homo sapiens <400> 1 Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro 1 5 10 15 Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu 20 25 30 Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr 35 40 45 Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly 50 55 60 Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp 65 70 75 80 Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp 85 90 95 Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly 100 105 110 Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val 115 120 125 Asp Pro Leu Thr Ile Thr Ser Ser Ser Ser Ser Asp Gly Val Leu Thr 130 135 140 Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro 145 150 155 160 Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 165 170 175 <210> 2 <211> 525 <212> DNA <213> homo sapiens <400> 2 atggacatcg ccatccacca cccctggatc cgccgcccct tctttccttt ccactccccc 60 agccgcctct ttgaccagtt cttcggagag cacctgttgg agtctgatct tttcccgacg 120 tctacttccc tgagtccctt ctaccttcgg ccaccctcct tcctgcgggc acccagctgg 180 tttgacactg gactctcaga gatgcgcctg gaaaaggaca ggttctctgt caacctggat 240 gtgaagcact tctccccaga ggaactcaaa gttaaggtgt tgggagatgt gattgaggtg 300 catggaaaac atgaagagcg ccaggatgaa catggtttca tctccaggga gttccacagg 360 aaataccgga tcccagctga tgtagaccct ctcaccatta cttcatccct gtcatctgat 420 ggggtcctca ctgtgaatgg accaaggaaa caggtctctg gccctgagcg caccattccc 480 atcacccgtg aagagaagcc tgctgtcacc gcagccccca agaaa 525 <210> 3 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> TAT protein transduction domain <400> 3 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 10 <210> 4 <211> 186 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 4 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Asp Ile Ala Ile 1 5 10 15 His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe His Ser Pro Ser 20 25 30 Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu Glu Ser Asp Leu 35 40 45 Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu Arg Pro Pro Ser 50 55 60 Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu Ser Glu Met Arg 65 70 75 80 Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val Lys His Phe Ser 85 90 95 Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val Ile Glu Val His 100 105 110 Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe Ile Ser Arg Glu 115 120 125 Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp Pro Leu Thr Ile 130 135 140 Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val Asn Gly Pro Arg 145 150 155 160 Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile Thr Arg Glu Glu 165 170 175 Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 <210> 5 <211> 190 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 5 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ser Gly Phe Met 1 5 10 15 Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe 20 25 30 His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu 35 40 45 Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu 50 55 60 Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu 65 70 75 80 Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val 85 90 95 Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val 100 105 110 Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe 115 120 125 Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp 130 135 140 Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val 145 150 155 160 Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile 165 170 175 Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 190 <210> 6 <211> 189 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 6 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Ser Gly Phe Asp 1 5 10 15 Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro Phe His 20 25 30 Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu Leu Glu 35 40 45 Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr Leu Arg 50 55 60 Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly Leu Ser 65 70 75 80 Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp Val Lys 85 90 95 His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp Val Ile 100 105 110 Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly Phe Ile 115 120 125 Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val Asp Pro 130 135 140 Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly Val Leu Thr Val Asn 145 150 155 160 Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro Ile Thr 165 170 175 Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 180 185 <210> 7 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Polyhistidine tag <400> 7 Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met 20 <210> 8 <211> 207 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 8 Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro Phe Phe Pro 35 40 45 Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly Glu His Leu 50 55 60 Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser Pro Phe Tyr 65 70 75 80 Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe Asp Thr Gly 85 90 95 Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val Asn Leu Asp 100 105 110 Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val Leu Gly Asp 115 120 125 Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp Glu His Gly 130 135 140 Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro Ala Asp Val 145 150 155 160 Asp Pro Leu Thr Ile Thr Ser Ser Ser Ser Ser Asp Gly Val Leu Thr 165 170 175 Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg Thr Ile Pro 180 185 190 Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro Lys Lys 195 200 205 <210> 9 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 9 Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Gly Ser Gly Phe Met Asp Ile Ala Ile His His Pro Trp Ile Arg Arg 35 40 45 Pro Phe Phe Pro Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe 50 55 60 Gly Glu His Leu Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu 65 70 75 80 Ser Pro Phe Tyr Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp 85 90 95 Phe Asp Thr Gly Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser 100 105 110 Val Asn Leu Asp Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys 115 120 125 Val Leu Gly Asp Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln 130 135 140 Asp Glu His Gly Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile 145 150 155 160 Pro Ala Asp Val Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp 165 170 175 Gly Val Leu Thr Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu 180 185 190 Arg Thr Ile Pro Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala 195 200 205 Pro Lys Lys 210 <210> 10 <211> 210 <212> PRT <213> Artificial Sequence <220> <223> Fusion protein <400> 10 Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15 Arg Gly Ser His Met Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 20 25 30 Gly Ser Gly Phe Asp Ile Ala Ile His His Pro Trp Ile Arg Arg Pro 35 40 45 Phe Phe Pro Phe His Ser Pro Ser Arg Leu Phe Asp Gln Phe Phe Gly 50 55 60 Glu His Leu Leu Glu Ser Asp Leu Phe Pro Thr Ser Thr Ser Leu Ser 65 70 75 80 Pro Phe Tyr Leu Arg Pro Pro Ser Phe Leu Arg Ala Pro Ser Trp Phe 85 90 95 Asp Thr Gly Leu Ser Glu Met Arg Leu Glu Lys Asp Arg Phe Ser Val 100 105 110 Asn Leu Asp Val Lys His Phe Ser Pro Glu Glu Leu Lys Val Lys Val 115 120 125 Leu Gly Asp Val Ile Glu Val His Gly Lys His Glu Glu Arg Gln Asp 130 135 140 Glu His Gly Phe Ile Ser Arg Glu Phe His Arg Lys Tyr Arg Ile Pro 145 150 155 160 Ala Asp Val Asp Pro Leu Thr Ile Thr Ser Ser Leu Ser Ser Asp Gly 165 170 175 Val Leu Thr Val Asn Gly Pro Arg Lys Gln Val Ser Gly Pro Glu Arg 180 185 190 Thr Ile Pro Ile Thr Arg Glu Glu Lys Pro Ala Val Thr Ala Ala Pro 195 200 205 Lys Lys 210 <210> 11 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 11 ctatcagaat tcgacatcgc catccaccac 30 <210> 12 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 12 taccgactcg agctatttct tgggggctgc 30 <210> 13 <211> 549 <212> DNA <213> Artificial Sequence <220> <223> DNA fragment <400> 13 ctatcagaat tcgacatcgc catccaccac ccctggatcc gccgcccctt ctttcctttc 60 cactccccca gccgcctctt tgaccagttc ttcggagagc acctgttgga gtctgatctt 120 ttcccgacgt ctacttccct gagtcccttc taccttcggc caccctcctt cctgcgggca 180 cccagctggt ttgacactgg actctcagag atgcgcctgg aaaaggacag gttctctgtc 240 aacctggatg tgaagcactt ctccccagag gaactcaaag ttaaggtgtt gggagatgtg 300 attgaggtgc atggaaaaca tgaagagcgc caggatgaac atggtttcat ctccagggag 360 ttccacagga aataccggat cccagctgat gtagaccctc tcaccattac ttcatccctg 420 tcatctgatg gggtcctcac tgtgaatgga ccaaggaaac aggtctctgg ccctgagcgc 480 accattccca tcacccgtga agagaagcct gctgtcaccg cagcccccaa gaaatagctc 540 gagtcggta 549
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150139908A KR20170040648A (en) | 2015-10-05 | 2015-10-05 | Pharmaceutical composition for preventing or treating diabetic foot ulcer |
| PCT/KR2016/011093 WO2017061750A1 (en) | 2015-10-05 | 2016-10-05 | Pharmaceutical composition for prevention or treatment of diabetic foot ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150139908A KR20170040648A (en) | 2015-10-05 | 2015-10-05 | Pharmaceutical composition for preventing or treating diabetic foot ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170040648A true KR20170040648A (en) | 2017-04-13 |
Family
ID=58487839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150139908A KR20170040648A (en) | 2015-10-05 | 2015-10-05 | Pharmaceutical composition for preventing or treating diabetic foot ulcer |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20170040648A (en) |
| WO (1) | WO2017061750A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316003B1 (en) * | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US8771689B2 (en) * | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
| NZ583803A (en) * | 2007-09-07 | 2012-12-21 | Ind Res Ltd | Agents with angiogenic and wound healing activity |
| US8796419B2 (en) * | 2010-05-19 | 2014-08-05 | Hoffmann-La Roche Inc. | Hydrophobic interaction chromatography method |
-
2015
- 2015-10-05 KR KR1020150139908A patent/KR20170040648A/en not_active Application Discontinuation
-
2016
- 2016-10-05 WO PCT/KR2016/011093 patent/WO2017061750A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017061750A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10336798B2 (en) | Growth differentiation factor 15 (GDF-15) polypeptides | |
| US20220370560A1 (en) | Ptd-smad7 therapeutics | |
| CN101490080A (en) | Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same | |
| CN107530400A (en) | The method for the illness for destroying or removing cell is needed using the peptide treatment from NF-M | |
| RU2426745C2 (en) | Recombinant chimeric protein of neutrophil and girugen inhibition factor and pharmaceutical composition containing it | |
| KR20200090889A (en) | CDKL5 expression variants and CDKL5 fusion proteins | |
| KR20220139079A (en) | Cell penetrating peptide variants and uses therof | |
| KR20160121122A (en) | Composition for preventing hair loss or promoting hair growth | |
| JP2016536306A (en) | Human relaxin analog, pharmaceutical composition thereof and pharmaceutical use thereof | |
| US8586544B2 (en) | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component | |
| KR20170040648A (en) | Pharmaceutical composition for preventing or treating diabetic foot ulcer | |
| US20210379146A1 (en) | Method to restore or improve cognitive functions | |
| US10385113B2 (en) | Engineered FGF compositions and methods of use thereof | |
| US20140303093A1 (en) | Micro-utrophin polypeptides and methods | |
| EP2275437A1 (en) | Polypeptide and pharmaceutical composition containing the polypeptide | |
| US11633456B2 (en) | Compositions and methods for promoting hair growth | |
| EP4032901A1 (en) | Recombinant human neuregulin derivatives and use thereof | |
| KR101671197B1 (en) | Pharmaceutical composition for arthritis containing glutaredoxin 1 fusion protein | |
| CN112500493A (en) | Recombinant human neuregulin derivative and application thereof | |
| KR101761550B1 (en) | Pharmaceutical composition for arthritis containing PEA15 fusion protein | |
| US20100168386A1 (en) | Fusion protein carrying neurotrophin across the blood-brain barrier, encoding gene and uses thereof | |
| WO2020050751A1 (en) | Igf-1-long chimeric protein for stroke treatment | |
| KR20170143216A (en) | Fusion protein comprising FNDC5 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |